Meeting
2018 Genitourinary Cancers Symposium
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
Authors
Nizar M. Tannir
UT MD Anderson Cancer Center, Houston, TX
Nizar M. Tannir , Alice C. Fan , Richard J. Lee , Bradley Curtis Carthon , Othon Iliopoulos , James Walter Mier , Manish R. Patel , Funda Meric-Bernstam , Angela DeMichele , Martin Henner Voss , James J. Harding , Ramaprasad Srinivasan , Geoffrey Shapiro , Melinda L. Telli , Pamela N. Munster , Richard D. Carvajal , Yonchu Jenkins , Samuel H. Whiting , Johanna C. Bendell , Todd Michael Bauer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02071862
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 603)
DOI
10.1200/JCO.2018.36.6_suppl.603
Abstract #
603
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
First Author: Funda Meric-Bernstam
Poster
2016 ASCO Annual Meeting
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
First Author: Funda Meric-Bernstam
Poster
2016 ASCO Annual Meeting
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
First Author: Angela DeMichele
Poster
2019 Genitourinary Cancers Symposium
CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.
First Author: Nizar M. Tannir